Long-term Efficacy of a Triptorelin 3-month Depot in Girls with Central Precocious Puberty

Overview

Journal Ann Pediatr Endocrinol Metab

Specialty Pediatrics

Date 2024 Jan 31

PMID 38291760

Authors

Kyu Hyun Park

Si-Hwa Gwag

Yu Jin Kim

Lindsey Yoojin Chung

Eungu Kang

Hyo-Kyoung Nam

Young-Jun Rhie

Kee-Hyoung Lee

Affiliations

Soon will be listed here.

Abstract

Purpose: Three-month gonadotropin-releasing hormone agonists (GnRHas) are expected to achieve better compliance in patients with central precocious puberty (CPP) compared to the monthly formulation. However, 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment.

Methods: In this retrospective study, 69 Korean girls with CPP were prescribed either triptorelin pamoate (TP) 3-month depot (n=29) or triptorelin acetate (TA) 1-month depot (n=40) and were followed for 1 year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.

Results: Baseline characteristics were similar between the 2 groups. In the TP 3-month depot group, 27 of 29 patients (93.1%) exhibited suppressed luteinizing hormone level (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection. The degree of bone age advancement in the TP 3-month depot group decreased from 1.8±0.4 years at the start of treatment to 0.6±0.5 years at 1-year posttreatment. The gain in predicted adult height (PAH) 1 year after the end of treatment was similar between the TP 3-month and TA 1-month depot groups (5.2±3.1 and 5.3±2.4 cm, respectively; p=0.875).

Conclusion: A 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. For patient convenience, we suggest a 3-month GnRHa regimen as a promising CPP treatment option.

References

Fu J, Liang J, Zhou X, Prasad H, Jin J, Dong G . Impact of BMI on gonadorelin-stimulated LH peak in premenarcheal girls with idiopathic central precocious puberty. Obesity (Silver Spring). 2015; 23(3):637-43. DOI: 10.1002/oby.21010. View

Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino A, Antoniazzi F . Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol. 1999; 141(2):140-4. DOI: 10.1530/eje.0.1410140. View

Vatopoulou A, Roos E, Daniilidis A, Dinas K . Long-term effects of treatment of central precocious puberty with gonadotropin-releasing hormone analogs every three months. Gynecol Endocrinol. 2020; 36(12):1124-1126. DOI: 10.1080/09513590.2020.1770723. View

Neely E, Wilson D, Lee P, Stene M, Hintz R . Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr. 1995; 127(1):47-52. DOI: 10.1016/s0022-3476(95)70255-5. View

Klein K, Barnes K, Jones J, Feuillan P, Cutler Jr G . Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab. 2001; 86(10):4711-6. DOI: 10.1210/jcem.86.10.7915. View

Fuld K, Chi C, Neely E . A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr. 2011; 159(6):982-7.e1. DOI: 10.1016/j.jpeds.2011.05.036. View

Comite F, Cutler Jr G, Rivier J, Vale W, Loriaux D, Crowley Jr W . Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report. N Engl J Med. 1981; 305(26):1546-50. DOI: 10.1056/NEJM198112243052602. View

Lasorella S, Porto R, Iezzi M, Pistone C, Marseglia G, Verrotti A . Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of Central precocious puberty (CPP): a retrospective study. Gynecol Endocrinol. 2019; 36(4):338-340. DOI: 10.1080/09513590.2019.1655726. View

Ramos C, Canton A, Seraphim C, Faria A, Tinano F, Mendonca B . Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25 mg). J Pediatr Endocrinol Metab. 2021; 34(11):1371-1377. DOI: 10.1515/jpem-2021-0142. View

10.

Chung L, Kang E, Nam H, Rhie Y, Lee K . Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center. J Korean Med Sci. 2021; 36(34):e219. PMC: 8405405. DOI: 10.3346/jkms.2021.36.e219. View

11.

Guaraldi F, Beccuti G, Gori D, Ghizzoni L . MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol. 2015; 174(3):R79-87. DOI: 10.1530/EJE-15-0590. View

12.

Lee H, Yoon J, Hwang J . Luteinizing Hormone Secretion during Gonadotropin-Releasing Hormone Stimulation Tests in Obese Girls with Central Precocious Puberty. J Clin Res Pediatr Endocrinol. 2016; 8(4):392-398. PMC: 5197996. DOI: 10.4274/jcrpe.3091. View

13.

Lazar L, Padoa A, Phillip M . Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab. 2007; 92(9):3483-9. DOI: 10.1210/jc.2007-0321. View

14.

Baek J, Nam H, Jin D, Oh Y, Rhie Y, Lee K . Age of menarche and near adult height after long-term gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2014; 19(1):27-31. PMC: 4049550. DOI: 10.6065/apem.2014.19.1.27. View

15.

Carel J, Blumberg J, Seymour C, Adamsbaum C, Lahlou N . Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol. 2005; 154(1):119-24. DOI: 10.1530/eje.1.02056. View

16.

Bertelloni S, Massart F, Einaudi S, Wasniewska M, Miccoli M, Baroncelli G . Central Precocious Puberty: Adult Height in Girls Treated with Quarterly or Monthly Gonadotropin-Releasing Hormone Analog Triptorelin. Horm Res Paediatr. 2015; 84(6):396-400. DOI: 10.1159/000441497. View

17.

Bhatia S, Neely E, Wilson D . Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics. 2002; 109(2):E30. DOI: 10.1542/peds.109.2.e30. View

18.

Martinez-Aguayo A, Hernandez M, Beas F, Iniguez G, Avila A, Sovino H . Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. J Pediatr Endocrinol Metab. 2006; 19(8):963-70. DOI: 10.1515/jpem.2006.19.8.963. View

19.

Yang J, Song Q, Gao S, Gao Y, Shang X, Li G . Efficacy of Leuprorelin 3-Month Depot (11.25 mg) Compared to 1-Month Depot (3.75 mg) for Central Precocious Puberty in Chinese Girls: A Prospective Cohort Study. Int J Endocrinol. 2023; 2022:1043293. PMC: 9800096. DOI: 10.1155/2022/1043293. View

20.

Swerdloff R, Heber D . Superactive gonadotropin-releasing hormone agonists. Annu Rev Med. 1983; 34:491-500. DOI: 10.1146/annurev.me.34.020183.002423. View